Introduction
Cytomegalovirus (CMV) infection is a frequent cause of morbidity and mortality in transplant recipients who suffer from serious complications such as interstitial pneumonia, retinitis, gastrointestinal disease, hepatitis, and other visceral disease. Ganciclovir has been shown to be effective in improving or halting the progression of those CMV diseases1), and has been used alone or in combination with CMV antibody-enriched immunoglobulin (CMV-IG)1,2). The problem is that a major side effect associated with ganciclovir is myelosuppression, causing leukocytopenia in transplantation patients3). In addition, the transplantation patients are normally treated with immunosuppressants like cyclosporine (CsA), tacrolimus, or others. These drugs also sometimes cause myelosuppression, resulting in leukocytopenia4,5). Therefore, clinicians working on transplantation often encounter a situation in which ganciclovir is hard to administer for CMV disease.
We report here the first case in which active CMV infection was treated successfully by only CMV-IG in a renal transplant recipient. After this treatment with CMV-IG, disappearance of CMV from the patient's plasma was confirmed by a polymerase chain reaction (PCR)-based assay. The test is qualitative but was used semiquantitatively. A 64-year-old Japanese man underwent renal tansplantation. CMV infection was monitored sequentially by the PCR-based AMPLICOR(R) CMV test (using plasma as source material) and antigenemia asay. AMPLICOR(R) is a qualitative test, but was used semiquantitatively by preparing a series of dilutions of each plasma specimen with human plasma that was pooled in advance and was proved CMV-negative by this kit: +, positive; -, native. The results of antigenemia assay are expressed as positive cells per 50,000 peripheral blood leukocytes, (PBL). CTM, cefotiam; IPM/CS, imipenem/cilastatin: FOM, fosfomycin; MoAb, monoclonal antibody; CMV-IG, cytomegalovirus antibodyenriched immunoglobulin. These antibitics, CMV-IG, OKT3 MoAb, and methylprednisolone were administered intravenously. Azathioprine, mizoribine, prednisolone, and tacrolimus were given per os and the numbers shown are the volume of the medicine (unit, mg). 
Discussion
One group stated that single therapeutic use of CMV-IG is not recommended, although its combination with ganciclovir was hopeful8).
Some clinicians suspected that using CMV-IG alone might have been effective against CMV infection. However, there were no data to support this, because CMV infection has been hard to diagnose to date. Viral culture took several days to yield results. Direct CMV antigen detection (antigenemia assay) resolved the problem of time, but its snesitivity still remained insufficient, 
